Haleon (HLN) Income from Continuing Operations (2021 - 2023)
Haleon (HLN) posted Income from Continuing Operations of 1521652211.48 for Q4 2023, up 190.91% on a QoQ basis from 523069797.97 in Q2 2023, and up 24.86% year-over-year from 1218672525.66 in Q4 2022.
Haleon (HLN) Income from Continuing Operations (2021 - 2023) Analysis & Trends
Haleon's Income from Continuing Operations history runs 3 years deep, the most recent figure standing at 1521652211.48 for Q4 2023.
- Quarterly Income from Continuing Operations rose 24.86% year-over-year to 1521652211.48 in Q4 2023, while the trailing twelve-month figure through Dec 2023 was 3926140113.14 (changed N/A YoY) and the FY2025 annual result came in at 2215097364.33, up 17.48% from the prior year.
- Income from Continuing Operations was 1521652211.48 for Q4 2023 at Haleon, up from 523069797.97 in the prior quarter.
- Across five years, Income from Continuing Operations topped out at 1675577184.73 in Q4 2021 and bottomed at 523069797.97 in Q2 2023.
- A 3-year average of 1110926033.36 and a median of 1141255713.97 in 2022 frame the typical range for Income from Continuing Operations.
- Annual changes were most pronounced in 2022 — Income from Continuing Operations decreased 27.27% — and 2023, when it grew 24.86%.
- Haleon's Income from Continuing Operations stood at 1675577184.73 in 2021, then declined by 27.27% to 1218672525.66 in 2022, then increased by 24.86% to 1521652211.48 in 2023.
- Business Quant data shows HLN's Income from Continuing Operations at 1521652211.48 in Q4 2023, 523069797.97 in Q2 2023, and 662745578.03 in Q2 2023.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 88.07 Bn | 86.20 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 35.75 Bn | 32.01 Bn | 1.97 Bn | 370.00 Mn |
| 3 | Zoetis | 31.84 Bn | 29.90 Bn | 1.62 Bn | 601.00 Mn |
| 4 | Takeda Pharmaceutical | 27.18 Bn | 23.12 Bn | 4.39 Bn | -3.58 Bn |
| 5 | United Therapeutics | 23.09 Bn | 20.93 Bn | 648.10 Mn | 274.90 Mn |
| 6 | RedHill Biopharma | 21.32 Bn | 21.32 Bn | - | - |
| 7 | Viatris | 19.96 Bn | 18.16 Bn | 1.16 Bn | 176.40 Mn |
| 8 | Neurocrine Biosciences | 17.66 Bn | 16.34 Bn | 800.70 Mn | 197.90 Mn |
| 9 | Elanco Animal Health | 12.44 Bn | 12.02 Bn | 785.00 Mn | 57.00 Mn |
| 10 | Vireo Growth | 10.53 Bn | 10.38 Bn | 59.30 Mn | -22.50 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2023 | 1.52 Bn |
| Jun 30, 2023 | 523.07 Mn |
| May 3, 2023 | 662.75 Mn |
| Dec 31, 2022 | 1.22 Bn |
| Sep 20, 2022 | 1.06 Bn |
| Dec 31, 2021 | 1.68 Bn |